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Abstract
Objective: Short QT syndrome (SQTS) is an inherited cardiac channelopathy, 
but at present little information is available on its pharmacological treatment. 
SQT3 variant (linked to the inward rectifier potassium current IK1) of SQTS, 
results from a gain-of-function mutation (Kir2.1 D172N) in the KCNJ2-
encoded channels, which is associated with ventricular fibrillation (VF). 
Using biophysically-detailed human ventricular computer models, this study 
investigated the potential effects of quinidine, disopyramide, and E-4031 
on SQT3. Approach: The ten Tusscher et  al model of human ventricular 
myocyte action potential (AP) was modified to recapitulate the changes in 
IK1 due to heterozygous and homozygous forms of the D172N mutation. 
Wild-type (WT) and mutant WT-D172N and D172N formulations were 
incorporated into one-dimensional (1D) and 2D tissue models with transmural 
heterogeneities. Effects of drugs on channel-blocking activity were modelled 
using half-maximal inhibitory concentration (IC50) and Hill coefficient (nH) 
values. Effects of drugs on AP duration (APD), effective refractory period 
(ERP) and QT interval of pseudo-ECGs were quantified, and both temporal 
and spatial vulnerability to re-entry was measured. Re-entry was simulated 
in the 2D ventricular tissue. Main results: At the single cell level, the drugs 
quinidine, disopyramide, and E-4031 prolonged APD at 90% repolarization 
(APD90), and decreased maximal transmural voltage heterogeneity (δV); this 
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caused the decreased transmural dispersion of APD90. Quinidine prolonged 
the QT interval and decreased the T-wave amplitude. Furthermore, quinidine 
increased ERP and reduced temporal vulnerability and increased spatial 
vulnerability, resulting in a reduced susceptibility to arrhythmogenesis 
in SQT3. In the 2D tissue, quinidine was effective in terminating and 
preventing re-entry associated with the heterozygous D172N condition. 
Quinidine exhibited significantly better therapeutic effects on SQT3 than 
disopyramide and E-4031. Significance: This study substantiates a causal link 
between quinidine and QT interval prolongation in SQT3 Kir2.1 mutations 
and highlights possible pharmacological agent quinidine for treating SQT3 
patients.
Keywords: short QT syndrome, computational modelling, arrhythmia, 
quinidine, disopyramide, E-4031
S  Supplementary material for this article is available online
(Some figures may appear in colour only in the online journal)
Introduction
Short QT syndrome (SQTS) is a disorder in the electrical function of the heart, and it is 
associated with high risk of arrhythmias and of sudden cardiac death (SCD) (Gussak et al 
2000, Gaita et al 2003, Schimpf et al 2005). The SQTS phenotype is characterized by less 
than 360 ms with a range of 220–360 ms and a higher, symmetrical T-wave amplitude on the 
electrocardiogram (ECG). The ‘short QT interval’ was first discovered as a new clinical entity 
by Gusssk et al (2000) in 2000 and first described with arrhythmias and a high incidence of 
SCD in families with SQTS by Gaita et al (2003) in 2003. The basis for SQTS associated 
with various mutations in 6 different genes have been found: KCNH2 (Brugada et al 2004), 
KCNQ1 (Bellocq et al 2004), KCNJ2 (Priori et al 2005), CACNA1C (Antzelevitch et al 2007), 
CACNB2b (Antzelevitch et al 2007), and CACNA2D1 (Templin et al 2011). Among these 
mutations, either a gain-in-function of the potassium channel (linked to KCNH2, KCNQ1, and 
KCNJ2 gene) or a loss-in-function of the calcium channel (linked to CACNA1C, CACNB2b, 
and CACNA2D1 gene) has been observed.
Among the mutations is a pair of complementary nucleotide bases substitute from aspar-
tic acid (also known as aspartate) to sparagine at position 172 in KCNJ2 (which encodes 
the Kir2.1 channel protein) in patients exhibiting a history of palpitations, presyncope, and 
syncope symptoms (Priori et al 2005). Analysis of wild-type (WT) Kir2.1, of Kir2.1 D172N 
mutation under heterozygous (WT-D172N) homozygous (D172N) conditions, revealed the 
mutation led to changes in the inward rectifier potassium current (IK1) channels, which results 
in a gain-in-function, producing an increase of IK1 (Priori et al 2005). Previous studies have 
been shown that increased IK1 in SQT3 shortened the action potential duration (APD) and the 
effective refractory period (ERP), and stabilized rotors in computational models of human 
ventricular electrophysiology (Adeniran et al 2012).
The current first-line treatment for SQTS patients is an implantable cardioverter-defibrillator 
(ICD) device, but there is an increased risk of inappropriate treatment due to tachycardia, 
atrial fibrillation and, above all, of T-wave oversensing (Schimpf et al 2003). Moreover, the 
QT interval does not fall within the normal range over time by using the ICD. Clinical trials 
from Gaita et al (2004) concurrent with the in vitro findings demonstrated the antiarrhythmic 
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effectiveness of quinidine in patients with SQTS. They reported hydroquinidine administra-
tion prolonged the QT interval to the normal range. Moreover, quinidine also restored the QT 
interval/heart rate (QT-RR) relationship towards the normal range (Wolpert et al 2005). In a 
one-year follow-up, the SQT1 patients who treat hydroquinidine remained asymptomatic, and 
no further episode of arrhythmias was detected. However, the mechanisms by which quinidine 
prolongs QT interval and terminates and prevents arrhythmias in SQTS have still not yet been 
fully elucidated. However, possibly due to a lack of phenotypically accurate experimental 
models, there has hitherto not been any detailed investigation of how the quinidine prolongs 
QT interval and terminates and prevents ventricular arrhythmias in SQTS. Therefore, this 
study aimed to evaluate and compare the potential effects of quinidine in comparison to diso-
pyramide and E-4031 on ventricular depolarization and repolarization and susceptibility to 
re-entrant excitation waves in SQT3, by using multi-scale models of human ventricular elec-
trophysiology. These results may provide theoretical insights into the possible pharmacologi-
cal agent for treating SQT3 patients.
Methods
IK1 and human ventricular cell models
A contemporary human ventricular cell action potential (AP) model developed by ten Tusscher 
and Panfilov (2006) was used for the simulations in this study. The original equations for IK1 
in the ten Tusscher et al model was modified to incorporate the previously reported changes in 
IK1 for WT, mutant D172N and WT-D172N conditions (Priori et al 2005). The derived equa-
tion of IK1 for WT, WT-D172N and D172N conditions (McPate et al 2008) is available in the 
supplementary materials (stacks.iop.org/PM/38/1859/mmedia).




= − Iion + Istim
Cm
 (1)
where V is the cell membrane potential; t is time; Cm is the membrane capacitance per unit 
area; Istim is the external stimulus current; Iion is the sum of membrane currents. Particularly, 
the component of the late sodium current (INaL) from the ORd model (O’Hara et al 2011) was 
incorporated. Equation (1) was numerically integrated using the forward Euler method with a 
time step of 0.02 ms. APs were elicited with an S1-S2 protocol consisting of 20 S1 stimuli and 
an S2 stimulus. The S1 was applied at a basic cycle length (BCL) of 800 ms and -52 pA/pF 
strength for 1 ms. The S2 was applied at varying diastolic intervals (DI) after the AP evoked by 
the last S1. The ERP was measured as the smallest DI for which the overshot of the AP evoked 
by the S2 reached 80% of the AP evoked by the 20th S1.
Modelling the interactions between drugs and ion channels
A ‘simple pore block’ theory (Brennan et al 2009) was implemented to model drug-ion chan-
nel binding interactions. The reduced maximum conductances of the targeted channels in 
the presence of quinidine, disopyramide, and E-4031 were shown in tables 1–3, respectively. 
E-4031 is a specific blocker of delayed rectifier current (IKr) (Izumi et al 2010), and it does 
not affect sodium and calcium inward currents (Wettwer et al 1991). However, quinidine and 
disopyramide are multi-channel blockers (Sanchez-Chapula 1999, Gaita et al 2004). In this 
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study, several doses (4, 7, and, 10 03BCM for quinidine; 13 and 100 µM for disopyramide; 4, 
100, and 1000 nM for E-4031) were selected to assess the pharmacological effects on SQT3.
Effects of a combined action of blocking of multiple currents in the presence of quinidine 
at 4, 7, and 10 µM doses together with different theoretical (5% and 10%) and experimental 
(13.5%) blocking of INaCa.
Multicellular tissue simulations
Propagation of APs in multicellular tissue was described by using the monodomain equation:
∂V
∂t
= − Iion + Istim
Cm
+∇ · (D∇V) (2)
where ∇ is the gradient operator; D is the diffusion parameter modelling the intercellular 
electrical coupling via gap junctions. D was set to a value of 0.0008 cm2 ms−1 that gave a 
conduction velocity (CV) of a planar wave at 52 cm/s, close to the experimental CV of ~50 
cm s−1 through one-dimensional (1D) strand (Weingart 1977, Taggart et al 2000), except for 
a 5-fold decrease at the MIDDLE-EPI junction (Gima and Rudy 2002). The strand had a total 
length of 15 mm, with space step 0.15 mm, which is close to the cell length of a human ven-
tricular myocyte (80–150 µm). The corresponding length of each subregion was 3.75 mm for 
25 ENDO cells, 5.25 mm for 35 MIDDLE cells, and 6 mm for 40 EPI cells of the strand. The 
total length and proportion of each sub-region reliably reproduced a positive T wave (Zhang 
Table 1. Conductivities (% of the original value) in the presence of 4100, and 
1000 nM E-4031.
Current IC50 nH Conductivity Source
IKr 15.96  ±  0.04 nM 0.74  ±  0.05 80.0/22.1/2.9% McPate et al (2006, 2008)
Table 3. Conductivities (% of the original value) in the presence of 4, 7, and 10 µM 
quinidine.
Current IC50 nH Conductivity Source
IKr 0.62  ±  0.03 µM 0.93  ±  0.06 17.0/10.0/7.0% McPate et al (2006, 2008)
iKs 4.899 µM 1.4 56.9/37.5/27.0% Crumb et al (2016)
ito 3.487 µM 1.3 45.6/28.8/20.3% Crumb et al (2016)
iNa 14.6 µM 1.22 83.0/71.1/61.4% Kramer et al (2013)
iCaL 14.9  ±  1.5 µM 1.1  ±  0.1 83.2/72.9/61.29% Zhang and Hancox (2002)
iNaCa Not given Not given 95.0/90.0/86.52% Zhang and Hancox (2002)
iNaL 12.0  ±  0.7 µM 1.0 71.7/62.3/47.7% Wu et al (2008)
Table 2. Conductivities (% of the original value) in the presence of 13 and 100 µM 
disopyramide.
Current IC50 nH Conductivity Source
IKr 10.66  ±  0.04 µM 1.07  ±  0.05 39.1/5.4% McPate et al (2006, 2008)
iNa 168.4 µM 1.09 95/63.6% Yasuda et al (2015)
ito 259 µM 1.07 94.3/75.5% Sanchez-Chapula (1999)
iCaL 1036.7 µM 1.0 98.7/90.9% Yasuda et al (2015)
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et al 2008, Adeniran et al 2011, 2012). The pseudo-ECG was computed by using the Gima 
and Rudy approach (Gima and Rudy 2002). The electrode was placed at a site located 2.0 cm 
from the ENDO distal end. The pseudo-ECG morphology is consistent with the clinical data 
(Priori et al 2005).
A two-dimensional (2D) model was modelled by expanding the 1D strand (length of 15 
mm- x direction, 100 cells) into a sheet with a width (y direction, 1000 cells) of 150 mm (or 
with a larger size in order to measure the critical size of the tissue to support the formation 
and maintenance of re-entry). The spatial and time steps were the same as used in the 1D 
strand. Re-entry was initiated in 2D tissue by an S1–S2 protocol. An S1 (amplitude:  −52 pA/
pF; duration: 1 ms) was applied at ENDO distal end of the 2D tissue (length: 15 mm along 
the x- direction; width: 150 mm in the y- direction) to evoke a planar wave. During the vul-
nerable window (VW), an S2 with the same amplitude and duration as S1 was applied to 
the MIDDLE-EPI junction to evoke a unidirectional wave propagation. The S2 has variable 
spatial sizes. The critical size of the tissue to support re-entry was quantified as the minimum 
length of S2 that supports the formulation and maintenance of re-entry, which provides a 
reciprocal index of the spatial vulnerability of ventricle to re-entry: the smaller the critical 
size, the easier the initiation of re-entry (Zhang et al 2008).
Results
Effects of quinidine, disopyramide, and E-4031 on SQT3 in the single cell APs
The ten Tusscher et al human ventricular cell model (ten Tusscher and Panfilov 2006) incor-
porating SQT3 IK1 formulations (Adeniran et al 2012) gave AP characteristics which were in 
excellent agreement with experimental data from human ventricular myocytes (Priori et al 
2005). Alternations to IK1 due to SQT3 mutations accelerated the repolarization phase of APs 
as shown in figure 1. The D172N mutation resulted in shortening of APD, with the D172N 
condition exerting a more profound effect than the WT-D172N condition. The measured 
APD90 was 302 ms for the ENDO (figure 1(a)), 406 ms for the MIDDLE (figure 1(d)), and 
304 ms for the EPI (figure 1(g)) in WT, which was shortened, respectively, to 273, 357, and 
274 ms in WT-D172N and to 261, 341, and 262 ms in D172N condition. The abbreviated APD 
resulted largely from increased IK1 during the late phase of AP repolarization as shown by the 
time course of IK1 and the I–V phase plot in figures 1(b), (c), (e), (f), (h) and (i).
The effects of drug interactions simulated on APD prolongation from representative ENDO 
myocytes under WT-D172N and D172N condition are summarized in figure  2. APD90 in 
WT-D12N condition was prolonged to 278, 293, 299, 288, 291, 321, 340, and 341 ms in the 
presence of 4, 100, and 1000 nM E-4031, 13 and 100 µM disopyramide, and 4, 7, and 10 
µM quinidine, respectively, and in D172N condition was prolonged to 266, 279, 284, 274, 
276, 303, 319, and 320 ms, respectively. Quinidine produced a significant prolongation of 
APD90, bringing it much closer to that in WT condition. The observed resting membrane 
potential (RP) values were  −84.65, −85.61, −85.42, −86.06, and  −85.97 mV for the WT, 
WT-D172N, WT-D172N  +  4 µM quinidine, D172N, and D172N  +  4 µM quinidine condi-
tions, respectively.
Effects of quinidine, disopyramide, and E-4031on SQT3 in the 1D strand model
The simulated effects of all drug interactions simulated on pseudo-ECG are shown in figure 3. 
Supra-threshold stimulus (−52 pA/pF) was applied to the ENDO distal end, initiating elec-
trical excitation propagation towards MIDDLE and EPI parts in figure 3(a) (for WT-D172N 
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condition), (b) (for WT-D172N  +  4 µM quinidine condition), (e) (for D172N condition), and 
(f) (for D172N  +  4 µM quinidine condition). From this electrical excitation wave, pseudo-
ECG traces were computed as shown in figures 3(c) and (g). In these simulation results, quini-
dine, disopyramide, and E-4031 prolonged the QT intervals on the ECGs and reduced the 
T-wave amplitude. The QT interval was prolonged from 322 ms in WT-D172N condition to 
328, 346, 353, 340, 347, 380, 395, and 397 ms in the presence of 4, 100, and 1000 nM E-4031, 
13, and 100 µM, and 4, 7, and 10 µM quinidine, respectively, and and from 318 ms in the 
D172N condition to 323, 328, 333, 338, 364, 371, 375 ms, respectively. Then we further mea-
sured the rate dependence of ventricular CV (shown in supplementary materials). It shows 
that quinidine decreased ventricular conduction. At a rate of 75 b.p.m. (Pacing Cycle Length 
(PCL)  =  800 ms), the measured CV was 52 cm s−1 for the WT, 51 cm/s for the WT-D172N, 
47 cm/s for the D172N, 41 cm s−1 for the WT-D172N  +  10 µM quinidine, and 36 cm/s for the 
D172N  +  10 µM quinidine conditions. The decreased CV was due to the blocked sodium cur-
rent as shown in table 2, as no change in the intercellular coupling was considered.
In order to explain the decreased T-wave amplitude seen in figure 3(c), we examined the 
effects of quinidine on the membrane potential heterogeneity (δV) during APs, as well as 
transmural APD dispersion across the strand. Figures 4(a) and (b) show simulated ENDO, 
MIDDLE, and EPI APs with WT-D172N, and WT-D172N  +  4 µM quinidine conditions 
whilst figures 4(c) and (d) show corresponding time-course plots of the δV between differ-
ent cell types. The δV maximal between both MIDDLE-EPI and ENDO-MIDDLE APs was 
smaller with actions of drugs than before (see figures 4(e) and (f)). Figure 5(a) shows the 
distribution of APD90 for WT, WT-D172M and WT-D172N  +  4 µM quinidine conditions. 
Figure 1. Simulated AP profiles, IK1 traces and I–V relationships in WT, mutant WT-
D172N and D172N conditions. AP profiles for ENDO (a), MIDDLE (d), and EPI 
(g) cells. Corresponding IK1 traces for ENDO (b), MIDDLE (e), and EPI (h) cells. 
Instantaneous I–V relations for ENDO (c), MIDDLE (f), and EPI (i) cells.
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Quinidine decreased APD90 dispersion of APD90 in the 1D strand in figure 5(b). Figures 5(c) 
and (d) show the maximal spatial gradient of APD90 in drug-in-action conditions.
The ERP was prolonged in all drug-in-action conditions compared to the mutant conditions 
(see figure 6). ERP restitution (ERP-R) in the presence of quinidine showed a rightward shift, 
with decreased maximal slopes, which is associated with decreased instability of re-entrant 
excitation waves (Xie et al 2002), indicating antiarrhythmic effects of quinidine on D172N 
mutation. Then we quantified the vulnerability of tissue to unidirectional conduction block. 
Results of bidirectional conduction block, unidirectional conduction block, and bi-directional 
conduction are shown in figures 6(e)–(g), respectively. Figures 6(h) and (i) demonstrate the 
width of the VW. The VW decreased from 15 ms in WT-D172N to 7 ms in WT-D172N  +  4 
µM quinidine condition, and from 36 ms in D172N to 11 ms in D172N  +  4 µM quinidine 
condition.
Effects of quinidine, disopyramide, and E-4031 on SQT3 in 2D model
Further simulations were performed utilizing an idealized area of the 2D model to investigate 
the effects of quinidine, disopyramide, and E-4031 on the dynamic behaviours of re-entrant 
excitation waves. The results are shown in figure 7, in which snapshots of re-entrant excitation 
Figure 2. Simulated effects of quinidine, disopyramide, and E-4031 on SQT3 in single 
ENDO cell APs. AP profiles for mutant WT-D172N (a) and D172N (c) conditions by 
using the modified model. Measured APD90 for mutant WT-D172N (b) and D172N 
(d) conditions.
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waves from WT, WT-D172N, and WT-D172N  +  4 µM quinidine conditions are shown. In 
WT condition (see figures 6(a)–(d)), re-entrant waves were unstable and non-stationary as the 
tip of the re-entry meandered out of the tissue boundaries leading to self-termination, whereas 
augmented IK1 in the WT-D172N condition (see figures 6(f)–(i)) helped to sustain re-entrant 
excitation waves. Snapshots of simulated pharmacological effects of quinidine on re-entry in 
WT-D172N condition are shown in figures 6(k)–(n). Quinidine terminated re-entrant excita-
tion waves in the WT-D172N condition. Figures 6(e), (j) and (o) show a recording of the 
evolution of the AP of an EPI cell in the tissue in WT, WT-D172N, and WT-D172N  +  4 µM 
quinidine conditions, respectively.
Figure 3. Space-time plot of AP prolongation across a 1D strand and the simulated 
pseudo-ECG and QT intervals. (a) Space-time plot of AP prolongation in WT-D172N 
condition. (b) Space-time plot of AP prolongation in WT-D172N  +  4 µM quinidine 
condition. (c) Superimposed pseudo-ECGs in WT-D172N  +  drugs conditions. 
(d) Corresponding QT intervals in WT-D172N  +  drugs conditions. (e) Space-time plot 
of AP prolongation in D172N condition. (f) Space-time plot of AP prolongation in 
D172N  +  4 µM quinidine condition. (g) Superimposed pseudo-ECGs in D172N  +  drugs 
conditions. (h) Corresponding QT intervals in D172N  +  drugs conditions.
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We then proceeded to measure the minimal spatial length of a premature S2 stimulus that 
provides a sufficient substrate for the formulation and maintenance of re-entry. Quinidine, 
disopyramide, and E-4031 prolonged the minimal length of S2; the minimal length was pro-
longed from 78 mm in WT-D12N condition to 79, 81, 82, 85, 87, 107, 110, and 112 mm in 
the presence of 4, 100, and 1000 nM E-4031, 13 and 100 µM disopyramide, and 4, 7, and 10 
µM quinidine, respectively, and prolonged from 68 mm in D172N condition to 70, 73, 74, 76, 
78, 90, 95, and 97 mm, respectively. Prolongation of APD due to the action of drugs increased 
the wavelength of the wave and thus increased the minimal length of S2, which supports the 
notion that in SQT3 tissue with the application of quinidine, re-entrant excitation waves occur 
harder than in the drug-free SQT3 tissue.
Figure 4. Membrane potential heterogeneity (δV) between ENDO, MIDDLE, and EPI 
cells. (a) and (b) ENDO, MIDDLE, and EPI APs in WT-D172N and WT-D172N  +  4 
µM quinidine conditions, respectively. (c) and (d) Corresponding plots of δV against 
time. (e) and (f) Maximal δV during repolarization process between MIDDLE-EPI cells.
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Discussion
Summary of the major findings
The proband with the KCNJ2 D172N mutation had a QTc interval of 315 ms, where her 
35-year-old father had a QTc of 320 ms (Priori et al 2005). There is clinical evidence to dem-
onstrate the efficacy of quinidine in patients with SQTS (Gaita et al 2004, Wolpert et al 2005, 
Kaufman, 2007, Milberg et al 2007). Gaita et al reported that hydroquinidine prolonged a QT 
interval, which increased from 263  ±  12 ms to 362  ±  25 ms (calculated QT from 290  ±  13 ms 
to 405  ±  26 ms). Wolpert et al described that quinidine was an effective drug for SQTS with a 
mutation in HERG by restoring normal rate dependence of the QT interval and rendering ven-
tricular tachycardia (VT)/ventricular fibrillation (VF) non-inducible. In the present study, with 
the use of quinidine, mimicking the effects on SQT3, we found that the QT interval extended 
from 322 ms to 380, 395, and 397 ms in the presence of 4, 7, and 10 µM quinidine, which is 
within the normal range of QT interval between 363 and 421 ms.
Our major findings are as follows. (i) Quinidine prolonged APD of the ventricular cells. 
(ii) Quinidine prolonged ventricular cell APD90 inhomogeneously across the strand, thereby 
decreased the maximal membrane potential heterogeneity (δV) and decreased transmural 
Figure 5. APD90 distribution and its spatial gradient in a 1D strand. (a) Spatial 
distribution of APD90 in WT, WT-D172N, and WT-D172N  +  4 µM quinidine 
conditions. (b) The spatial gradient of APD90 in WT, WT-D172N, and WT-D172N  +  4 
µM quinidine conditions. (c) and (d) The maximal spatial gradient of APD90 in WT-
D172N and D172N conditions, respectively.
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dispersion, which combined to contribute the decreased T-wave amplitude. (iii) Quinidine 
increased ERP and reduced temporal and increased spatial vulnerability to initiate and sus-
tain re-entry, resulting in a reduced susceptibility of ventricular tissue associated with SQT3 
to arrhythmogenesis. (iv) Quinidine prevented and terminated re-entrant excitation waves. 
Figure 6. Rate-dependent ERP and vulnerable window in WT, WT-D172N, D172N, 
and drug-in-action conditions. (a) and (b) Rate-dependent ERP restitution (ERP-R) 
curves in WT-D172N and D172N conditions, respectively. (c) and (d) Slopes of ERP-R 
curves in WT-D172N and D172N conditions, respectively. (e) Bidirectional conduction 
block. (f) Unidirectional conduction block. (g) Bidirectional conduction. (h) and (i) 
Measured VW width in WT-D172N and D172N conditions, respectively.
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(v) Quinidine exhibited significantly better therapeutic effects on SQT3 than disopyramide 
and E-4031.
Antiarrhythmic mechanisms of quinidine on SQT3
Our data constitute new evidence that the anti-arrhythmic effects of quinidine on SQT3 asso-
ciated with Kir2.1 D172N mutation involve both decrease tissue susceptibility to the initiation 
of re-entry and prevention and termination of re-entry (terminating VF). An increase in ERP 
generated by actions of quinidine prolonged the wavelength of ventricular excitation waves 
and less likelihood for re-entrant excitation wave to be formed in a limited ventricular tissue 
mass. We found that, once formed, re-entry was unstable in the presence of quinidine.
Tissue susceptibility to the genesis of re-entry can be indexed by its temporal and spatial 
vulnerability. In our simulations, quinidine prolonged ventricular repolarization time due to the 
prolongation of APD and ERP, and subsequently resulted in a decreased temporal vulnerability 
(the width of VW). However, prolongation of ERP markedly increased the critical size of the 
re-entrant substrate, leading to an increased spatial vulnerability to re-entry. This provides a 
means for decreased ventricular tissue susceptibility to re-entry with the use of quinidine.
Figure 7. Simulated drug effects in 2D idealized human ventricular tissue, with 
standard excitation parameters, of size 15 mm  ×  150 mm, and of the standard S1-S2 
protocol. (a), (f) and (k) A planar wave generated by S1 at the ENDO distal end in 
the WT, WT-D172N, WT-D172N  +  4 µM quinidine conditions, respectively. Snapshot 
at time  =  10 ms. (b), (g) and (l) The S2 was applied to the MIDDLE-EPI junction 
during the VW of the tissue (WT: 340 ms; WT-D172N: 310 ms; WT-D172N  +  4 µM 
quinidine: 350 ms). (c), (h) and (m) Developed re-entrant excitation waves. Snapshots 
at time  =  750 ms. (d), (i) and (n) Snapshots of the re-entrant excitation waves at 
time  =  2000 ms. Quinidine terminated re-entrant excitation waves in the WT-D172N 
condition. (e), (j) and (o) Evolution of the AP of a cell in WT, WT-D172N, and 
WT-D172N  +  4 µM quinidine conditions, respectively.
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Limitations
The ten Tusscher and Panfilov (2006) model was used here to simulate cellular electrical AP 
of human ventricular myocytes; potential limitations of this model have been discussed else-
where (ten Tusscher and Panfilov 2006, Zhang et al 2008, Adeniran et al 2011, 2012). This 
study aimed to predict the effects of drugs on SQT3 by using purely cellular electrophysiol-
ogy, and as such did not consider the effects of electrical remodelling or fibrosis. Evidence 
of electrical remodelling in SQTS is currently lacking; nevertheless, this may play important 
roles in re-entrant arrhythmias in SQTS. On the other hand, our model did not consider car-
diac mechanical contraction, which has previously been suggested to be affected in SQTS 
patients (Schimpf et al 2008, Adeniran et al 2013, Frea et al 2015), and may affect the phar-
macological effects of drugs on SQTS.
Another limitation is that the action of drugs at the ion channel level did not incorporate 
voltage-, state-, frequency-dependent block effects. Regarding the experimental conditions, 
many factors, including oxygen, the concentration of ions, temperature, and pH (Cardona 
et al 2010, Mirams et al 2012), which influence the binding of drugs to ion channels would 
be required and modelled. Nevertheless, whilst it is useful to make potential limitations of the 
present study explicit, there are not anticipated to change the fundamental conclusions drawn 
in our study.
Conclusion
Alterations in IK1 have previously been implicated in genesis and maintenance of VF asso-
ciated with SQT3. Significantly, previous studies demonstrated the efficacy of quinidine in 
patients with SQTS. Our data indicate that quinidine not only helps to terminate re-entry 
but also decreases the susceptibility of human ventricular tissue to the genesis of re-entry. 
Our study identifies distinct factors at cell and tissue levels that underlie these antiarrhythmic 
changes. In conclusion, the findings of this simulation study add to the growing weight of 
evidence that quinidine may be a potential therapeutic agent for SQT3.
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